Designing antibodies for the inhibition of gastrin activity in tumoral cell lines (2008)
Barderas, R., Shochat, S., Timmerman, P., Hollestelle, M.J., Martínez-Torrecuadrada, J.L., Höppener, J.W.M., ...
Gastrin and its derivatives are becoming important targets for immunotherapy of pancreatic, gastric and colorectal tumors. This study was conducted to design antibodies able to block gastrin binding...
Affinity maturation of antibodies assisted by in silico modeling (2008)
Barderas, R., Desmet, J., Timmerman, P., Meloen, R., Casal, J.I.
Rational engineering methods can be applied with reasonable success to optimize physicochemical characteristics of proteins, in particular, antibodies. Here, we describe a combined CDR3 walking...
Large scale production and downstream processing of a recombinant porcine parvovirus vaccine (2002)
Maranga, L., Rueda, P., Antonis, A.F.G., Vela, C., Langeveld, J.P.M., Casal, J.I., ...
Porcine parvovirus (PPV) virus-like particles (VLPs) constitute a potential vaccine for prevention of parvovirus-induced reproductive failure in gilts. Here we report the development of a large scale...
Martinez-Torrecuadrada, J.L., Langeveld, J.P.M., Venteo, A., Sanz, A., Dalsgaard, K., Hamilton, W.D.O., ...
Antigenic structure of the capsid protein of rabbit haemorrhagic disease virus (1998)
Martinez-Torrecuadrada, J.L., Cortés, E., Vela, C., Langeveld, J.P.M., Meloen, R.H., Dalsgaard, K., ...
Mapping the antigenic structure of porcine parvovirus at the level of peptides (1998)
Kamstrup, S., Langeveld, J., Botner, A., Nielsen, J., Schaaper, W.M.M., Boshuizen, R.S., ...
Langeveld, J.P.M., Casal, J.I., Cortes, E., Swart, R.L. De, Vela, C., ...
A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic...
Sedlik, C., Dridi, A., Deriaud, E., Saron, M. F., Rueda, P., Sarraseca, J., ...
We previously demonstrated that chimeric porcine parvovirus-like particles (PPV:VLP) carrying heterologous epitopes, when injected intraperitoneally into mice without adjuvant, activate strong CD4+...
Casal, J I, Langeveld, J P, Cortés, E, Schaaper, W W, Van Dijk, E, Vela, C, ...
The N-terminal domain of the major capsid protein VP2 of canine parvovirus was shown to be an excellent target for development of a synthetic peptide vaccine, but detailed information about number of...
Hurtado, A, Rueda, P, Nowicky, J, Sarraseca, J, Casal, J I
Canine parvovirus capsids are composed of 60 copies of VP2 and 6 to 10 copies of VPl. To locate essential sites of interaction between VP2 monomers, we have analyzed the effects of a number of VP2...
Serologic markers in early stages of African horse sickness virus infection.
Martínez-Torrecuadrada, J L, Díaz-Laviada, M, Roy, P, Sánchez, C, Vela, C, Sánchez-Vizcaíno, J M, ...
Fifteen horses were experimentally infected with African horse sickness virus (AHSV) serotype 4. To learn more about the time course of production and specificity of AHSV-specific antibodies, sera...
Langeveld, J P, Casal, J I, Osterhaus, A D, Cortés, E, De Swart, R, Vela, C, ...
A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic...
Langeveld, J P, Casal, J I, Vela, C, Dalsgaard, K, Smale, S H, Puijk, W C, ...
Ten antigenic sites on canine parvovirus (CPV) were mapped with a complete set of overlapping nonapeptides of the capsid proteins VP1 and VP2: five of these sites were recognized by sera from...
Control of oligomeric enzyme thermostability by protein engineering.
Ahern, T J, Casal, J I, Petsko, G A, Klibanov, A M
The ability to control the resistance of an enzyme to inactivation due to exposure to elevated temperatures is essential for the understanding of thermophilic behavior and for developing rational...
Sedlik, C., Dridi, A., Deriaud, E., Saron, M. F., Rueda, P., Sarraseca, J., ...
We previously demonstrated that chimeric porcine parvovirus-like particles (PPV:VLP) carrying heterologous epitopes, when injected intraperitoneally into mice without adjuvant, activate strong CD4+...
Casal, J I, Langeveld, J P, Cortés, E, Schaaper, W W, Van Dijk, E, Vela, C, ...
The N-terminal domain of the major capsid protein VP2 of canine parvovirus was shown to be an excellent target for development of a synthetic peptide vaccine, but detailed information about number of...
Hurtado, A, Rueda, P, Nowicky, J, Sarraseca, J, Casal, J I
Canine parvovirus capsids are composed of 60 copies of VP2 and 6 to 10 copies of VPl. To locate essential sites of interaction between VP2 monomers, we have analyzed the effects of a number of VP2...
Serologic markers in early stages of African horse sickness virus infection.
Martínez-Torrecuadrada, J L, Díaz-Laviada, M, Roy, P, Sánchez, C, Vela, C, Sánchez-Vizcaíno, J M, ...
Fifteen horses were experimentally infected with African horse sickness virus (AHSV) serotype 4. To learn more about the time course of production and specificity of AHSV-specific antibodies, sera...
Langeveld, J P, Casal, J I, Osterhaus, A D, Cortés, E, De Swart, R, Vela, C, ...
A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic...
Langeveld, J P, Casal, J I, Vela, C, Dalsgaard, K, Smale, S H, Puijk, W C, ...
Ten antigenic sites on canine parvovirus (CPV) were mapped with a complete set of overlapping nonapeptides of the capsid proteins VP1 and VP2: five of these sites were recognized by sera from...
Control of oligomeric enzyme thermostability by protein engineering.
Ahern, T J, Casal, J I, Petsko, G A, Klibanov, A M
The ability to control the resistance of an enzyme to inactivation due to exposure to elevated temperatures is essential for the understanding of thermophilic behavior and for developing rational...